Monday, October 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 20, 2026

Building Intelligent Healthcare Systems The Role of AI, EHRs, and Advanced Analytics

View original at globenewswire.com
Building Intelligent Healthcare Systems The Role of AI, EHRs, and Advanced Analytics Ottawa, Feb…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Investments in clinician training and workflow redesign correlate strongly with higher ROI

    80% confidence

  • The global healthcare IT market is valued at approximately USD 880 billion in 2025

    80% confidence

  • AI and generative technologies will automate documentation, generate real-time insights, and support prescriptive decision-making

    80% confidence

  • North America currently leads the healthcare IT market with 41% revenue share

    80% confidence

  • Platformization and industry consolidation will accelerate, as buyers favor comprehensive, integrated solutions with measurable ROI

    80% confidence

  • Organizations that treat EHR and IT changes as cultural and operational shifts, not just technical updates, realize greater long-term benefits

    80% confidence

  • Asia Pacific is emerging as the fastest-growing region due to rising healthcare digitization efforts

    80% confidence

  • Healthcare IT has evolved from a back-office function to a mission-critical strategic asset

    80% confidence

  • Healthcare organizations deploying AI report improvements in care quality, patient safety, and predictability of outcomes

    80% confidence

  • The global healthcare IT market is projected to exceed USD 3.7 trillion by 2035, growing at a compound annual growth rate (CAGR) of over 15%

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com